Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

NCT06633757 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Ciliary Dyskinesia (PCD)

Interventions

DRUG: RCT1100

Sponsor

ReCode Therapeutics